Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.33 |
| ▸ | CA1 | P00915 | 4/20 | 0.33 |
| ▸ | CA9 | Q16790 | 4/20 | 0.33 |
| ▸ | PREP | P48147 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.31 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CASR | P41180 | 2/20 | 0.30 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.30 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.30 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2177637 | 0.81 | CASR (0.44) | CASRMTNR1AMTNR1B | |
| SCHEMBL16244976 | 0.79 | SLC22A1 (0.55) | CA12CA1CA9SLC22A1OPRM1 | |
| SCHEMBL19745616 | 0.78 | CA12 (0.41) | CA12CA1CA9PREPHSP90AA1 | |
| SCHEMBL15242469 | 0.76 | CA1 (0.42) | CA12CA1CA9PREPHSP90AA1 | |
| SCHEMBL3280559 | 0.76 | LMNA (0.43) | CA12CA1CA9HSP90AA1HSP90AB1 | |
| SCHEMBL343105 | 0.74 | CA12 (0.40) | CA12CA1CA9HSP90AA1HSP90AB1 | |
| SCHEMBL21391528 | 0.74 | CA12 (0.40) | CA12CA1CA9PREPHSP90AA1 | |
| SCHEMBL30514294 | 0.74 | CA12 (0.40) | CA12CA1CA9PREPHSP90AA1 | |
| SCHEMBL2680521 | 0.72 | CA12 (0.37) | CA12CA1CA9HSP90AA1HSP90AB1 | |
| SCHEMBL9987962 | 0.72 | GPBAR1 (0.46) | CA12CA1CA9HSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9090539-B2 | Compounds and methods for preparing substituted 3-(1-amino-2-methylpentane-3-yl)phenyl compounds | AMPAC FINE CHEMICALS LLC (US) | 2015-07-28 | — | — | US | disclosed |
| US-20140350283-A1 | Compounds and Methods for Preparing Substituted 3-(1-amino-2-methylpentane-3-yl)phenyl Compounds | AMPAC FINE CHEMICALS LLC | 2014-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140350283-A1 | Compounds and Methods for Preparing Substituted 3-(1-amino-2-methylpentane-3-yl)phenyl Compounds | QDPR, SRMS, SPR | CA12 4404/4885CA1 3314/4885CA9 2361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.